Companies / DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc.

Nasdaq: DMACCIK 1401040MINNEAPOLIS, MN

Financials

Revenue—
Net income$-32.77M
Total debt—
Cash$5.13M
Diluted EPS—
Shares outstanding53.9M

Ownership

53.9M shares outstanding · as of Aug 3, 2026
1.0%Insiders
Ownership
Insiders1.01%544,499
Institutions23.71%12,784,019
Public float75.28%40,597,179

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 9

View all →
Insider% of sharesShares
Giuffre Randall MichaelDirector
0.74%398,587
Parsons James T.Director
0.18%97,949
Semba Charles PaulingDirector
0.09%47,963
Kellen ScottCFO & Secretary
——
Krop JulieChief Medical Officer
——
Kuntz RichardDirector
——
Lewis TanyaDirector
——
O'Connor Daniel J.Director
——
Pauls Dietrich JohnCEOPresident & CEO · Director
——

Institutional holders 98

View all →
HolderValue% of shares
Cooperman Leon G$16.08M3.75%
BlackRock, Inc.$15.86M4.18%
Millennium Management LLC$6.33M1.73%
Paragon Associates & Paragon Associates II Joint Venture$5.92M1.62%
Vanguard Group Inc$5.76M1.34%
Geode Capital Management, LLC$5.29M1.45%
State Street Corporation$4.55M1.20%
Morgan Stanley$4.36M1.02%
First Manhattan Co. LLC.$3.22M0.75%
Bleichroeder LP$3.04M0.71%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jan 2, 2026Parsons James T.
Director
GrantCommon Stock$85.0K+10K
+11.49%
97,949
0.18% of shares
low
Jan 2, 2026Giuffre Randall Michael
Director
GrantCommon Stock$52.0K+6K
+1.57%
398,587
0.74% of shares
low
Jan 2, 2026Semba Charles Pauling
Director
GrantCommon Stock$28.2K+3K
+7.52%
47,963
0.09% of shares
low
Jun 1, 2026Semba Charles Pauling
Director
GrantStock Option (right to buy)—+40K
40,412
0.07% of shares
low
Jun 1, 2026Pauls Dietrich John
CEO
GrantStock Option (right to buy)—+380K
380,000
0.70% of shares
low
Jun 1, 2026Parsons James T.
Director
GrantStock Option (right to buy)—+51K
51,189
0.09% of shares
low
Jun 1, 2026Giuffre Randall Michael
Director
GrantStock Option (right to buy)—+40K
40,412
0.07% of shares
low
Jun 1, 2026Krop Julie
Executive
GrantStock Option (right to buy)—+68K
67,500
0.13% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Trill ABPassive13G/A———
Dialectic Life Sciences SPV LLCPassive13G/A———
Cooperman Leon GPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
DMACCommon StockEquity25253X207BBG000LP4YD7